Blog

Shahin Gharakhanian MD 1H2021 COVID-19 Activities’ PROGRESS REPORT

* Utay, N. S., Asmuth, D. M, Gharakhanian, S., Contreras, M., Warner, C. D., & Detzel, C. J. (2021). Potential use of serum-derived bovine immunoglobulin/protein isolate for the management ofCOVID-19. Drug Development Research, 1–7. https://doi.org/10.1002/ddr.21841 * GARDEN (NCT04659109) is a multinational, multicenter, randomized, double-blind,...

Continue reading »

Shahin Gharakhanian MD 2020 COVID-19 Activities’ REPORT

On 30 December 2019 a ProMed email from the International Society of Infectious Diseases (IDSA) contained information on <Undiagnosed pneumonia in China>, thus alerting the world to what was to become the worst health crisis in 100 years. On 24 January 2020, the New England Journal of Medicine (2020, 382: 727-733) published a brief report from...

Continue reading »

4th Boston Biotechnology Virtual Summit

www.bostonbiotechnologysummit.com The 4th Boston ● Paris Biotechnology Virtual Summit ● Focus on Covid-19 – will be held, via a zoom platform, on Thursday 15 October 2020, 11 AM – 01 PM US EDT [17:00 – 19:00 EU CET] in three sequential panels as below. The Program Committee, listed below*, have convened renowned experts...

Continue reading »

Stroke is the Second Cause of Mortality Worldwide: ACTICOR-BIOTECH Expands ACTIMIS Stroke Study to the UNITED STATES — Shahin Gharakhanian MD Consulting LLC Leads Nationwide Project from Cambridge MA

Cambridge MA, 02.03.2020. Stroke is listed as the 2nd cause of mortality worldwide according to the World Health Organization. ACTICOR-BIOTECH [CEO: Dr Gilles AVENARD], a leading, fully-funded, PARIS-based, biotechnology company is assessing its novel agent ACT017 as an add on therapy to Standard of Care in AIS: Acute Ischemic Stroke. This year Acticor-Biotech...

Continue reading »

The 5th International Conference on Vaccine Research & Development

For the first time in the US, a joint presentation as an invited speaker (ref. below) @ the forthcoming 5th International Conference on Vaccine Research & Development (Boston/Newton, November 2019). This will focus on the clinical development program being initiated by PAR’IMMUNE [Biotech start-up: CEO Dr A. Lachgar, HQ in Lille, France] that...

Continue reading »

It Takes a Village to Develop a Safe and Efficacious New Therapeutic Agent Truly Responding to Patient Needs.

Since 2016, we have been diligently building bridges between Boston and European Biotechnologies as a way of accelerating the advent of new treatments in response to patient’s needs, globally. Collaboration is becoming an increasingly important component in the next stage of biotechnology’s evolution. There are at least three fundamental reasons: 1)  ...

Continue reading »